Trial Profile
A phase II trial of combined weekly bortezomib and tositumomab I-131 in patients with relapsed or refractory follicular non-Hodg
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Iodine-131 tositumomab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- 06 Oct 2021 Status changed from recruiting to discontinued.
- 24 Jan 2008 The expected completion date for this trial is now 1 May 2008.
- 25 Jul 2007 New trial record.